The Size of the Aptamers Market in Europe is valued at USD 43.51 Million in 2019 and estimated to reach USD 108.27 Million by the end of 2024, at a growing potential of 20.00 % during the forecast period 2019-2024.
Aptamers are oligonucleotides that bind to a target protein, lipid, or nucleic acid molecules with a high specificity. Due to the increasing number of opportunities I.e, drug discovery, biomarker discovery, and diagnostics segments in the market number of players entering the market. The potential of aptamers in diagnostics and therapeutics has been recognized by the launch of the first aptamer, Macugen. So, the European market for aptamers is expected to grow, which has been backed by advancements in technology with respect to selection processes and synthesis.
The Major factors driving the growth of the European market are an advancement in technology, Growing R&D investments in pharmaceutical and biotechnology industries, low cost and high efficacy of aptamers in binding. Stringent regulations in the use of aptamers, slow in reaching the market place due to regulatory hurdles may hinder the growth of the market.
This research report segmented and sub-segmented the Europe Aptamers Market into the following categories:
Some of the major companies dominating the Europe Aptamers market are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc, TriLink BioTechnologies Inc., and Vivonics, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Peptide Aptamers
5.1.2 Nucleic Acid Aptamers
5.1.2.1 DNA-Based Aptamers
5.1.2.2 RNA-Based Aptamers
5.1.2.3 XNA-Based Aptamers
5.2 By Application
5.2.1 Therapeutics Development
5.2.2 Diagnostics
5.2.3 Research and Developments
5.3 By End Users
5.3.1 Pharmaceutical Companies
5.3.2 Bio-Pharmaceutical Companies
5.3.3 Academic and Research Centers
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 AM Biotechnologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Aptagen
8.3 Aptamer Sciences Inc.
8.4 Aptamer Solutions Ltd
8.5 Aptus Biotech S.L.
8.6 Base Pair Biotechnologies Inc
8.7 NeoVentures Biotechnology Inc.
8.8 SomaLogic Inc
8.9 TriLink BioTechnologies Inc
8.10 Vivonics, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
